

THRU ONLINE FILING

September 23, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

Sub: Notice of Board Meeting and Trading Window Closure

Pursuant to Regulation 29 read with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on **Monday, 30th September, 2024**, to consider, inter-alia, integration and consolidation of the generics formulations business in the US market of M/s. Bayshore Pharmaceuticals LLC (wholly owned step-down subsidiary) into Unichem Pharmaceuticals (USA) Inc. (wholly owned subsidiary of Company's subsidiary) so as to consolidate all the Ipca Group's USA generics formulations business under one entity.

Pursuant to the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in shares of the Company for designated persons, directors, insiders and their immediate relatives has been closed from Monday, 23rd September 2024 in view of the above meeting of the Board of Directors of the Company.

The window closure will continue from 1st October 2024 till 48 hours after declaration of unaudited financial results of the Company for the 2nd quarter and half year ended 30th September 2024.

You are requested to kindly take this on your records.

Thanking you.

Yours faithfully,
For Ipca Laboratories Limited

Harish P. Kamath
Corporate Counsel & Company Secretary
ACS 6792

Ipca Laboratories Ltd.
www.ipca.com